摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate

中文名称
——
中文别名
——
英文名称
[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate
英文别名
——
[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate化学式
CAS
——
化学式
C12H17N2O8P
mdl
——
分子量
348.25
InChiKey
YTXSHVVEGWNQNN-DNRKLUKYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.9
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    155
  • 氢给体数:
    3
  • 氢受体数:
    8

文献信息

  • [EN] NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES<br/>[FR] DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDE ET LEUR UTILISATIONS
    申请人:METROBIOTECH LLC
    公开号:WO2017024255A1
    公开(公告)日:2017-02-09
    The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    本发明涉及烟酰胺单核苷酸衍生物的组合物及其使用方法。本发明还涉及制备烟酰胺单核苷酸衍生物的方法。本发明涉及含有烟酰胺单核苷酸衍生物的药物组合物和营养补充剂。本发明涉及使用烟酰胺单核苷酸衍生物的方法,促进细胞和组织中烟酰胺腺嘌呤二核苷酸(NAD+)水平的增加,用于治疗疾病和改善细胞和组织的存活。
  • Nicotinamide mononucleotide derivatives and their uses
    申请人:Metro International Biotech, LLC
    公开号:US10548913B2
    公开(公告)日:2020-02-04
    The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    本发明涉及烟酰胺单核苷酸衍生物的组合物及其使用方法。本发明还涉及制备烟酰胺单核苷酸衍生物的方法。本发明涉及含有烟酰胺单核苷酸衍生物的药物组合物和营养补充剂。本发明涉及使用烟酰胺单核苷酸衍生物的方法,该衍生物可促进细胞和组织中烟酰胺腺嘌呤二核苷酸(NAD+)细胞内水平的增加,用于治疗疾病和改善细胞和组织存活率。
  • NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES
    申请人:Metro International Biotech, LLC
    公开号:EP3331894A1
    公开(公告)日:2018-06-13
  • US9855289B2
    申请人:——
    公开号:US9855289B2
    公开(公告)日:2018-01-02
查看更多

同类化合物

烟酸单核苷酸 β-烟酰胺单核苷酸 3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓 but-3-yn-l-yl (((2R,3S,4R,5R)-5-(3-carbamoylpyridin-l-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) phosphate nicotinamide mononucleotide nicotinate D-ribonucleotide 1,4-dihydronicotinamide adenine dinucleotide α-Nicotinamid-mononucleotid 3-Carbamoyl-1-((2S,3S,4R,5S)-3,4-dihydroxy-5-phosphonooxymethyl-tetrahydro-furan-2-yl)-pyridinium NMNH Nicotinamide-benzimidazole dinucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(2-methoxyphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-(naphthalen-1-ylmethylamino)-5-oxopentyl]triazol-4-yl]ethyl phosphate 2-(1-adamantyl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 2-[1-[5-(benzhydrylamino)-5-oxopentyl]triazol-4-yl]ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-methylphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-phenylethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 5-phenoxypentyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-oxo-5-[(4-phenylphenyl)methylamino]pentyl]triazol-4-yl]ethyl phosphate 2-(1-benzyltriazol-4-yl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-fluorophenoxy)ethoxy]ethyl phosphate butyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 1-(3'-deoxy-3'-fluoro-β-D-xylofuranosyl)nicotinamide-5'-phosphate 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(benzyl phosphate) 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate) [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate beta-Nicotinamide mononucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl hydrogen phosphate 1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2R,3S,4R,5R)-5-(benzimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono phosphate [[(2R,3R,4R,5R)-5-amino-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate 1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [amino-[5-azanidyl-1-[5-[[[[5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxy-3-phosphonooxyoxolan-2-yl]imidazolidine-4,5-diid-4-yl]methyl]azanide [(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid Pyridinium, 3-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-naphthalen-1-yltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methyl hydrogen phosphate β-nicotinamide mononucleotide [(2R,3R,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2S,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [(2S,3S,4S,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid